<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77360">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066545</url>
  </required_header>
  <id_info>
    <org_study_id>CLS001-CO-PR-003</org_study_id>
    <nct_id>NCT02066545</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutanea Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutanea Life Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and efficacy of once-daily
      topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel
      in subjects with inflammatory acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in inflammatory lesion count from Baseline</measure>
    <time_frame>6, 9 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at each visit in inflammatory lesions, non-inflammatory lesions and total lesions</measure>
    <time_frame>1, 3, 6, 9 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline at each visit in inflammatory lesions, no-inflammatory lesions, and total lesions</measure>
    <time_frame>1, 3, 6, 9 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an Investigator's Global Assessment (IGA) of clear or almost clear (0 or 1) at each visit</measure>
    <time_frame>1, 3, 6, 9, and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a 2 grade reduction in the IGA at each visit</measure>
    <time_frame>1, 3, 6, 9, and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CLS001 topical gel 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLS001 topical gel 1.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLS001 topical gel 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLS001 Topical Gel</intervention_name>
    <arm_group_label>CLS001 topical gel 1%</arm_group_label>
    <arm_group_label>CLS001 topical gel 1.75%</arm_group_label>
    <arm_group_label>CLS001 topical gel 2.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female subjects with facial acne vulgaris, 12 years of age or
             older.

          -  Subjects with â‰¥20 inflammatory facial lesions (papules, pustules) inclusive of the
             nose, with a maximum of 9 inflammatory pustules.

          -  An Investigator's Global Assessment (IGA) of Moderate (3) or Severe (4)

        Exclusion Criteria:

          -  Subjects with acne conglobate, acne fulminans, and secondary acne (chloracne,
             drug-induced acne, polycystic ovarian syndrome, etc.)

          -  Subjects with greater that 75 facial non-inflammatory lesions (open and/or closed
             comedones; excluding the nose)

          -  Subjects with more than 2 facial nodulocystic lesions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Koher</last_name>
      <phone>818-788-5060</phone>
      <email>chin@drraoof.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Raoof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Gardina</last_name>
      <phone>858-292-8641</phone>
      <email>tgardina@skinsurgerymed.com</email>
    </contact>
    <investigator>
      <last_name>Dale Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giles</last_name>
      <phone>310-828-8887</phone>
      <email>mgilescsi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paul Yamauchi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, Inc.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Torres</last_name>
      <email>p.torresscr@comcast.net</email>
    </contact>
    <contact_backup>
      <last_name>Angela Garcia</last_name>
      <email>angie.garciascr@comcast.net</email>
    </contact_backup>
    <investigator>
      <last_name>Marta Rendon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belleair Research Center</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hue Luong</last_name>
      <phone>727-828-3353</phone>
      <email>huekluong@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gary L Heller, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Juneja</last_name>
      <phone>813-948-7550</phone>
      <phone_ext>402</phone_ext>
      <email>ejuneja@mooreclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Susan Barker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kenneth R. Beer, MD, PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Dunn, R.N., BSN</last_name>
      <phone>561-655-9055</phone>
      <email>mdunn@palmbeachcosmetic.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth R Beer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mangieri, RN</last_name>
      <phone>770-252-6900</phone>
      <email>kmangieri@medaphase.com</email>
    </contact>
    <investigator>
      <last_name>Mark Russell Ling, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Creasor, RN, CCRC</last_name>
      <phone>810-455-1612</phone>
      <email>jcreasor@hamzavi.com</email>
    </contact>
    <investigator>
      <last_name>Fasahat Hamzavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Horita</last_name>
      <phone>763-571-4200</phone>
    </contact>
    <investigator>
      <last_name>Steven Kempers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya E Salazar</last_name>
      <phone>505-247-4220</phone>
      <email>tsalazar@abqdermtrials.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo H Tschen, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Dermatology &amp; Cosmetic Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mussarrat Hussain</last_name>
      <phone>201-280-2127</phone>
      <email>mussarrathussain@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dendy Engelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York, Inc.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Hennessy, LPN</last_name>
      <phone>631-689-1900</phone>
      <email>chennessy@drcny.com</email>
    </contact>
    <investigator>
      <last_name>Elyse Rafal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vickie Ellis</last_name>
      <phone>336-841-2040</phone>
      <email>dcs3@northstate.net</email>
    </contact>
    <investigator>
      <last_name>Zoe Diana Draelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Ritter</last_name>
      <phone>919-781-2514</phone>
      <email>britter@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Adnan Nasir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brynne Thompson</last_name>
      <phone>615-383-9660</phone>
      <email>bthompson@tnclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Michael H Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Bauman, RN, BSN</last_name>
      <phone>512-287-6321</phone>
      <email>alicia.bauman@premier-research.com</email>
    </contact>
    <investigator>
      <last_name>Dayna Diven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Scott</last_name>
      <phone>979-774-5933</phone>
      <email>jscott@js-studies.com</email>
    </contact>
    <investigator>
      <last_name>Terry M Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estella Marquez, LVN</last_name>
      <phone>210-614-5557</phone>
      <email>emarquez@progclin.com</email>
    </contact>
    <investigator>
      <last_name>Mark Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Bland</last_name>
      <phone>509-343-3710</phone>
      <email>research@premierclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>William Werschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
